

# Ji-Youn Han

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/15871/publications.pdf>

Version: 2024-02-01

51  
papers

3,607  
citations

201575

27  
h-index

182361

51  
g-index

52  
all docs

52  
docs citations

52  
times ranked

4558  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 558-567.	0.5	43
2	Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2022, 14, 1512.	1.7	1
3	A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3105-3105.	0.8	0
4	Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 151, 8-15.	0.9	23
5	Symptom perception and functioning in patients with advanced cancer. <i>PLoS ONE</i> , 2021, 16, e0245987.	1.1	2
6	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2459-2469.	1.2	3
7	Amivantamab in EGFR Exon 20 Insertion-“Mutated Non-“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402.	0.8	320
8	Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100224.	0.6	6
9	Brigatinib Versus Crizotinib in ALK Inhibitor-“Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2091-2108.	0.5	156
10	Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-“Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	0.8	32
11	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9512-9512.	0.8	54
12	ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9601-9601.	0.8	1
13	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-“2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1681-1690.	5.1	92
14	JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9009-9009.	0.8	74
15	Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 636-648.	0.5	67
16	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-“Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). <i>Journal of Clinical Oncology</i> , 2018, 36, 2702-2709.	0.8	359
17	Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non-“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2027-2039.	13.9	691
18	Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-“Mediated Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2024-2033.	1.9	24

#	ARTICLE	IF	CITATIONS
19	EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion. <i>Lung Cancer</i> , 2018, 124, 71-75.	0.9	22
20	ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 678-687.	1.3	3
21	Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 1001-1011.	1.3	43
22	Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. <i>Oncotarget</i> , 2016, 7, 69450-69465.	0.8	60
23	A phase II study of nintedanib in patients with relapsed small cell lung cancer. <i>Lung Cancer</i> , 2016, 96, 108-112.	0.9	30
24	PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 627.	1.1	40
25	A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 465-472.	1.3	12
26	A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients. <i>Lung Cancer</i> , 2015, 88, 201-207.	0.9	55
27	Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 475-483.	1.1	62
28	The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. <i>Radiation Oncology</i> , 2014, 9, 283.	1.2	32
29	Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. <i>Lung Cancer</i> , 2014, 85, 161-167.	0.9	43
30	A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 137-142.	0.9	46
31	Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib. <i>Journal of Korean Medical Science</i> , 2013, 28, 1595.	1.1	4
32	A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1553-1560.	3.2	117
33	Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 74, 293-299.	0.9	24
34	A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. <i>Cancer</i> , 2011, 117, 2178-2185.	2.0	40
35	DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. <i>Cancer</i> , 2011, 117, 3201-3208.	2.0	22
36	Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy. <i>Pharmacogenomics Journal</i> , 2010, 10, 86-93.	0.9	15

#	ARTICLE	IF	CITATIONS
37	Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 63, 115-120.	0.9	91
38	Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2008, 113, 388-395.	2.0	27
39	Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. <i>Cancer</i> , 2008, 113, 799-807.	2.0	67
40	Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 59, 69-75.	0.9	90
41	Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive Disease Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1039-1045.	0.5	14
42	Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2007, 110, 138-147.	2.0	188
43	The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 54, 227-234.	0.9	55
44	Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2006, 106, 873-880.	2.0	23
45	Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non-Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin. <i>Journal of Clinical Oncology</i> , 2006, 24, 2237-2244.	0.8	293
46	A Phase II Study of Dose-Intensified Weekly Concomitant Administration of Cisplatin and Irinotecan in Chemonaive Patients with Extensive-Disease Small-Cell Lung Cancer. <i>Medical Oncology</i> , 2005, 22, 281-290.	1.2	4
47	Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2005, 104, 2759-2765.	2.0	13
48	Phase II Study of Irinotecan Plus Cisplatin Induction Followed by Concurrent Twice-Daily Thoracic Irradiation With Etoposide Plus Cisplatin Chemotherapy for Limited-Disease Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3488-3494.	0.8	45
49	The Correlation Between Gastric Cancer Screening Method and the Clinicopathologic Features of Gastric Cancer. <i>Medical Oncology</i> , 2003, 20, 265-270.	1.2	6
50	A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2003, 98, 1918-1924.	2.0	30
51	A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5909-14.	3.2	19